Omeros Files Application for FDA Approval of Cataract Surgery Drug

Omeros, a clinical stage biopharmaceutical company, has announced that has submitted a new drug application to the FDA for its OMS302, a drug for use during intraocular lens replacement surgery.

Advertisement

Omeros also intends to submit a marketing authorization application to the European Medicines Agency.

More Articles on Ophthalmology:
Global Surgical Ophthalmology Market to be Worth $9B by 2017
Valeant to Reduce Workforce by 15% After Bausch +Lomb Buyout
7 Recent Ophthalmologist Moves

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.